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ABSTRACT
Background. This study aimed to assess the influence of
disease- and patient-related factors on surgeons’ decisions
to refer patients with early-stage breast cancer (EBC) for
neoadjuvant systemic therapy (NST).
Methods. An online survey of United States surgeons
evaluated the influence of selected disease- and patient-
related factors on surgeons’ decisions, rated their influence
(individually and in combination), and provided a relative
ranking of jointly considered factors using best–worst
scaling.
Results. The participants in this study were 100 licensed
surgeons. The surgeons referred approximately 25 % of
EBC patients for NST to improve surgical management.
Approximately 75 % of the surgeons agreed that NST is
important for EBC, if only to improve surgical manage-
ment. More than half were ‘‘very likely’’ to refer EBC
patients for NST based on anatomicopathologic factors.
Less than 50 % were ‘‘very likely’’ to do so when con-
sidering tumor phenotype factors. Tumor size and lymph
node status were ranked highest in hypothetical patient
scenarios. Regarding combinations of factors, the impor-
tance of any single factor varied according to the
combinations presented. Less than half of the respondents
were ‘‘very familiar,’’ and half were ‘‘somewhat familiar’’
with NST guidelines for breast cancer. More than half of
the respondents were unaware that findings have shown
achievement of pathologic complete response (pCR) after
NST to be associated with improved survival.
Conclusions. Surgeons’ decision to refer for NST is
strongly driven by surgical management goals. Anatomi-
copathologic factors are more influential than tumor
phenotype. However, no single disease or patient factor
consistently drives the decision to refer for NST. Surgeons’
awareness of the association between pCR achievement
and longer survival could be improved.
The usual therapeutic approach for early-stage breast
cancer (EBC) consists of surgical tumor resection followed
by adjuvant systemic therapy with or without radiotherapy.
For patients with locally advanced breast cancer, neoad-
juvant systemic therapy (NST) is generally considered the
standard of care, and for selected patients with operable
breast cancer, NST has become an alternative to adjuvant
chemotherapy.
In randomized clinical trials, neoadjuvant chemotherapy
has shown equivalence to adjuvant chemotherapy in pro-
longing disease-free and overall survival.1–3 During the
past decade, the addition of human epidermal growth factor
receptor 2 (HER2)-targeted agents to neoadjuvant
chemotherapy for patients with HER2-positive breast
cancer has significantly increased pathologic complete
response (pCR) rates, more than for other subtypes, and
pCR has been associated with better outcomes.4–6 In par-
ticular, achievement of pCR was recently identified by the
United States (U.S.) Food and Drug Administration (FDA)
as a possible surrogate end point for accelerated approval
of new drugs in EBC,7 and this finding was used to support
the first accelerated approval of an anti-HER2 therapy
(Perjeta [pertuzumab] in combination with trastuzumab
and chemotherapy) for use in the neoadjuvant setting.8
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NST has several potential clinical advantages including
improved surgical options 2,3,9,10 and improved long-term
outcomes.2,10,11 Also, clinicians have leveraged the ability
to use NST to identify responders and nonresponders,
offering the potential for further tailoring of systemic
therapy options.12
This study aimed to assess the influence of disease- and
patient-related factors on surgeons’ decisions to refer
patients with EBC for NST.
METHODS
Study Approach and Implementation
An ad hoc review of the literature showed that referrals
for adjuvant therapy and its use for breast and other cancers
are influenced by patient and tumor characteristics, the
surgeon, and the care setting.13–17 However, less is known
about factors that affect referral for NST and its use for
breast cancer. This review informed identification of the
following 11 disease and patient factors associated with
referrals for NST:




• Estrogen receptor (ER) and progesterone receptor (PR)
status
• Inflammatory breast cancer (IBC)
• Involvement of axillary lymph nodes by clinical
assessment (lymph node status)
• Patient’s age
• Patient’s overall health and comorbidities
• Patient’s preference for timing of surgery
• Patient’s level of interest in breast-conservation
surgery.
Survey questions were developed to elicit the influence
of selected individual and disease factors on surgeons’
decisions using the following three assessments:
• Ratings to determine the influence of all 11 individual
disease and patient factors, independently, using a 4-
point Likert scale (from ‘‘very likely’’ to ‘‘very
unlikely’’ to refer for NST)
• Ratings to determine the influence of combinations of
four disease factors (i.e., status of 2 tumor markers,
lymph node involvement, and tumor size) using a 4-
point Likert scale
• Relative ranking to determine the influence of multiple
disease and patient factors when considered jointly.
The relative rankings were elicited using case 1 best–
worst scaling (BWS).18,19 Surgeons were presented with
three hypothetical and typical EBC patient scenarios, each
defined in terms of nine disease and patient factors. For
each scenario, surgeons determined whether they would
first refer the patient for NST, refer the patient for adjuvant
therapy, or proceed directly with surgery. In a series of
BWS questions, each with three disease and patient factors
determined by a predetermined experimental design with
known statistical properties, the participating surgeons
ranked the importance of each factor (e.g., 3-cm tumor,
HER2-positive status, and grade 2 invasive ductal carci-
noma) for each hypothetical patient.
The survey also included questions about respondents’
personal and practice characteristics. The survey was tested
and refined based on in-person semistructured pretest
interviews with a convenience sample of ten breast sur-
geons. The pretest participants confirmed that the list of
disease and patient factors was comprehensive. The final
survey is included as Supplementary Material.
All Global (New York, NY), a vendor specializing in
online surveys, programmed and hosted the online survey,
with 100 surgeons recruited from a web panel of physi-
cians. Physicians joined the panel via a double opt-in
process. All Global verified the American Medical Asso-
ciation (AMA) or American Osteopathic Association
(AOA) numbers of the panelists as well as their email and
work addresses. The panelists were invited to participate in
the survey via email. Respondents were required to be
board-certified or board-eligible surgeons practicing in the
United States who had performed breast cancer surgery for
at least 2 years since completing surgical training and had
completed at least 30 mastectomies or lumpectomies in the
year before the survey.
The study was reviewed and approved by RTI Interna-
tional’s institutional review board.
Statistical Analysis
The ratings of individual factors and combinations of
factors were summarized by means and standard devia-
tions. To analyze the BWS data, a logit model was used,
following the methods presented by Yuan et al.,20 to infer
the importance of disease and patient factors in the sur-
geons’ stated intention to refer hypothetical patients for one
of three treatment options (NST, adjuvant therapy, sur-
gery). One logit model was estimated for each hypothetical
patient profile. The estimated parameter for a factor can be
interpreted as the importance of that factor relative to the
most important factor, which was normalized to 1.
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RESULTS
All Global invited 1590 physicians in their U.S. web
panel to be screened for study eligibility, and 483
responded to the invitation. Of those who responded, 117
were eligible to participate. All 117 eligible participants
(100 %) were rescreened for specialty and consented to
participate. Of these eligible physicians who consented to
participate, 100 (85 %) completed the survey.
Respondent Characteristics
In September 2014, 100 surgeons licensed in 46 states
and the District of Columbia completed the survey.
Approximately three-fourths (73 %) of the respondents
were male. On the average, the respondents spent 74 % of
each week in direct patient care. All the respondents had
performed surgery significantly longer than 2 years (mean
17 ± 7 years) and had completed well over the required 30
lumpectomies or mastectomies in the previous year (mean
144 ± 149). Approximately one-half of the respondents
were involved in private individual (21 %) or group (32 %)
practices, and approximately one-fourth were involved in
academic/university (18 %) or cancer center-based (9 %)
practices. The remaining respondents were community
hospital-based practitioners (19 %). General surgeons and
surgical oncologists each comprised approximately one-
third of the respondents (36 and 33 %, respectively). Breast
surgeons comprised approximately one-fourth (26 %) of
the respondents. A total of 76 surgeons indicated that they
regularly presented at tumor boards and that 47 % of their
patients, on the average, were presented with EBC.
Identification of Aggressive Disease
From a list of disease factors provided, the respondents
most frequently selected IBC and skin/chest wall involve-
ment as two of the top five disease factors indicating tumor
aggressiveness (Fig. 1). Additionally, other anatomico-
pathologic factors (lymph node positivity and, to some
extent, tumor size) were selected more often than tumor
phenotype factors (HER2 status, ER/PR status, and histo-
logic grade/type), except for triple-negative breast cancer.
However, more than half of the surgeons selected most of
the phenotype factors (high histologic grade/histologic
type, HER2-positive status, triple-negative status) as the
top five indicators.
Disease- and Patient-Related Factors for NST Referral
Ratings of Individual Factors More than half of the
respondents were ‘‘very likely’’ to refer a patient with EBC
for NST based on each of the following anatomicopathologic
factors of aggressiveness: lymph nodes (52 %), large tumor
size (63 %), skin/chest wall involvement (79 %), and IBC
(79 %) (Fig. 2). Less than half of respondents were ‘‘very
likely’’ to refer a patient with EBC for NST based on the
following tumor phenotype factors of aggressiveness: ER/
PR-negative status (37 %), high histologic grade/histologic
type (39 %), HER2-positive status (42 %), and triple-
negative status (47 %). When the ‘‘very likely’’ and the
‘‘somewhat likely’’ ratings were combined, the similar total
percentages indicated that all these anatomicopathologic and
tumor phenotype factors were important in influencing a





















FIG. 1 Disease factors each selected
as one of five factors indicating tumor
aggressiveness. ER estrogen receptor,
HER2 human epidermal growth factor
receptor 2, IBC inflammatory breast
cancer, PR progesterone receptor
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In addition to disease factors, the surgeons rated the
influence that individual patient factors and patient-related
considerations have on NST referrals (Fig. 3). The fol-
lowing factors were most commonly listed as ‘‘very
important’’ or ‘‘somewhat important’’: patient’s interest in
breast-conservation surgery (84 %), tumor removal expe-
diency (71 %), willingness to receive chemotherapy
(84 %), overall health (75 %), and age (68 %). A lower
percentage of surgeons reported practical concerns such as
proximity to the treatment center (47 %) and insurance
coverage (28 %) as ‘‘very important’’ or ‘‘somewhat
important.’’
Ratings for Combinations of Factors Responses to the
questions about combinations of four factors (i.e., status of
2 tumor markers, lymph node involvement, and tumor size)
indicated that given a tumor phenotype, the likelihood of
referral for NST increased consistently with tumor size (T1
to T2 to T3) (Fig. 4). Lymph node status also appeared to
increase the likelihood of referral for NST, but its relative
influence decreased with tumor size. In general, differences
in tumor phenotype did not significantly affect the
likelihood of referral.
Rankings of Factors Considered Jointly in the Context of
Patient Scenarios Figure 5 presents hypothetical patient
scenarios and the within-scenario relative ranking of
disease and patient factors in the decision to refer a
patient for NST. The importance of the factors varied by
scenario, but tumor size and lymph node status were the
most highly rated disease factors for all three scenarios.
The patient scenarios excluded IBC and skin/chest wall
Very likely to refer
Somewhat likely to refer
Somewhat unlikely to refer



























FIG. 2 Ratings of likelihood that a
patient will be referred for NST, by
disease factor. ER estrogen receptor,
HER2 human epidermal growth factor
receptor 2, IBC inflammatory breast
cancer, NST neoadjuvant systemic
therapy, PR progesterone receptor. Note
Each respondent rated only the five
characteristics that he or she associated
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FIG. 3 Ratings of the importance of
individual patient factors and patient-
related considerations in the decision to
refer patients for consideration of NST.
BCS breast cancer surgery, NST
neoadjuvant systemic therapy
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involvement, which would be expected to dominate the
decision to refer for NST. Furthermore, although a
patient’s willingness to receive chemotherapy ranked
high in importance as an individual factor, we excluded
it from BWS-ranking questions because we considered it
an equally important factor for both neoadjuvant and
adjuvant systemic therapy.
Other Factors for NST Referral
Treatment Goals On the average, the surgeons reported
referring 48 % of patients with EBC to a medical
oncologist before resection. Of these patients, 52 % were
referred for NST to improve surgical management, whereas
25 % were referred to undergo NST for other reasons, and
21 % were referred for discussion of adjuvant therapy.
The majority of the surgeons (85 %) agreed that NST is
an important part of treatment for stages 1, 2, or 3 breast
cancer, even if only to improve surgical management so as
to ensure negative margins, convert inoperable cases to
operable cases, and/or convert mastectomy candidates to
lumpectomy candidates.
The percentages of surgeons who responded that the
following tumor-marker and other related information was
‘‘almost always’’ available to inform their decision to
perform surgery ranged from 60 to 73 %, depending on the
type of information, as follows: HER2 (61 %), ER/PR
(60 %), type/grade (70 %), lymph node status (73 %), and
tumor size (71 %). When this information was unavailable,
the percentage of respondents who would ‘‘almost always’’
wait for HER2 status information before performing sur-
gery was 33 % for stage 1 disease, 43 % for stage 2
disease, and 51 % for stage 3 disease.
Awareness of Evidence for NST Effectiveness Most
respondents ([90 %) reported some familiarity with
specific NSTs for breast cancer, although less than half
(40 %) were ‘‘very familiar’’ and approximately half
(51 %) were ‘‘somewhat familiar’’ with NST therapies.
Altogether, 96 % of the breast surgeons and 97 % of the
surgical oncologists reported being ‘‘very familiar’’ (65 and
45 %, respectively) or ‘‘somewhat familiar’’ (31 and 52 %,
respectively) with the NST therapies compared with 84 %
of the general surgeons who rated themselves as ‘‘very
familiar’’ (17 %) or ‘‘somewhat familiar’’ (67 %) with the
NST therapies. More than half of the respondents were
unaware of available evidence showing that patients who
had a pCR after NST were more likely to have improved
survival (event-free survival, disease-free survival, or
overall survival). Only 54 % of the breast surgeons, 45 %
of the surgical oncologists, and 31 % of the general
surgeons reported awareness of this evidence.
For further assessment of familiarity with NSTs and
evidence-supported use, the respondents were asked whe-
ther two scenarios might affect their decision to refer
patients for NST. First, if an FDA-approved therapy
showed a significant improvement in pCR rate, 39 % of the















































FIG. 4 The percentage of respondents ‘‘somewhat likely’’ or ‘‘very
likely’’ to refer a patient for NST, based on ER/PR status, HER2
status, and tumor size, by lymph node status. ER estrogen receptor,
HER2 human epidermal growth factor receptor 2, NST neoadjuvant
systemic therapy, PR progesterone receptor
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Scenario 1 patient characteristics
Scenario 2 patient characteristics























































Referrals: Surgery (42%), NST (38%), Adjuvant (20%)
Referrals: Surgery (22%), NST (61%), Adjuvant (17%)






















































































FIG. 5 Relative ranking of factors by hypothetical patient scenario
(n = 100). CI confidence interval. Note The vertical bars surrounding
each mean preference weight denote the 95 % CI about the point
estimate. ‘‘Tumor size,’’ ‘‘lack of preference for timing of surgery,’’
and ‘‘palpable and fixed lymph node’’ in patient scenarios 1, 2, and 3,
respectively, do not have the 95 % CI because all the other factors
were scaled relative to that factor
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likely’’ to consider referral for NST therapy. Second, if an
FDA-approved NST demonstrated significantly improved
long-term efficacy, 52 % of the respondents were ‘‘very
likely’’ and 36 % were ‘‘somewhat likely’’ to consider
referral for NST.
DISCUSSION
To our knowledge, no previously published studies have
investigated the stated importance of disease- and patient-
related factors in surgeons’ decisions to refer patients for
NST. Our survey showed that surgeons’ decisions to refer
for NST are strongly driven by surgical management goals.
Based on the ratings of the individual disease factors
assessed, IBC and skin/chest wall involvement were the
most influential disease factors driving referrals for NST.
Most patient factors and considerations also were rated
highly, but these percentages were lower than those for the
disease factors.
Overall, our survey found that anatomicopathologic
factors are more influential than tumor phenotype in the
decision to refer a patient for NST, suggesting that biologic
factors are simply not as important in surgeons’ thinking as
anatomicopathologic factors. However, the relative ranking
of factors in the three patient scenarios (excluding IBC and
skin/chest wall involvement) showed that no single disease
or patient factor (of the 9 examined) consistently drives the
decision to refer for NST. In fact, all the pre-identified
factors provided in the survey were important in the deci-
sion to refer for NST, but which factor dominated
depended on the other factors present.
Our survey results indicate that surgeons are at least
somewhat aware of NSTs and their appropriate use.
However, awareness among surgeons of the association
between achievement of pCR and longer survival could be
improved. A recent FDA-led meta-analysis 11 showed that
pCR in breast and lymph nodes was associated with
improved long-term survival compared with no pCR.
Furthermore, Cortazar et al.11 found the strongest associ-
ation between pCR and long-term survival among patients
with aggressive breast cancer subtypes such as triple-neg-
ative status; ER/PR-positive status, HER2-negative status,
and high-grade, and ER/PR-negative/HER2-positive dis-
ease status.
One interesting finding showed that tumor marker and
other related information was ‘‘almost always’’ available to
the surgeons in only 60–73 % of cases before surgery.
Furthermore, when HER2 status was unavailable, the per-
centage of the surgeons who would ‘‘almost always’’ wait
before performing surgery was only 33 % for stage 1 dis-
ease, only 43 % for stage 2 disease, and only 51 % for
stage 3 disease. Although knowledge of tumor phenotype
does not greatly alter the surgical resection plan, tumor size
and nodal status clearly have important roles relative to the
type of surgical approach for the breast and axilla. More-
over, knowledge of tumor phenotype is increasingly
considered in the selection of appropriate candidates for
NST. To that extent, educational efforts must focus on
increasing the integration of tumor biomarkers in the
treatment plan before surgery so as not to deprive appro-
priate candidates for NST from the opportunity to receive
it.
Although the pre-identified nature of the factors rated or
ranked by the surgeons was a possible limitation of the
study, the factors selected were informed by an ad hoc
review of the literature and pretested in interviews. Another
potential limitation of such a survey is that sample repre-
sentativeness of the study respondents and findings cannot
be determined. Physicians opted in both to the panel from
which they were recruited and to survey participation,
which potentially influenced sample representativeness.
Sample characteristics were not compared with those of
surgeons treating breast cancer in the United States. In
addition, the questions included in the survey and the
conclusions drawn from the surgeons’ responses to these
questions represent an exploration into surgeons’ practices
for the referral of breast cancer patients for NST. Given
this objective and the nature of the questions considered in
the survey, the data would not support meaningful formal
statistical inferences based on the patterns of the surgeons’
responses. Nevertheless, our results can inform the design
of future studies, which will allow meaningful statistical
tests around the issues we explored.
In summary, surgeons’ decisions to refer patients for
NST are made primarily to improve surgical outcomes.
Anatomicopathologic factors influence referral decisions
more than tumor phenotype factors, but although these
factors are important, no single pre-identified factor drives
the NST referral decision. Finally, less than half of sur-
geons responding were aware of the correlation between
pCR achievement and long-term survival, indicating that
this awareness could be improved and NST referral pos-
sibly considered more widely for patients with EBC.
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